Long-Sheng Chang

List of Publications by Year
in descending order

41 papers	1,165 citations	331259 21 h-index	377514 34 g-index
43 all docs	43 docs citations	43 times ranked	1414 citing authors

#	Article	IF	Citations
1	cDNA Microarray Analysis of Vestibular Schwannomas. Otology and Neurotology, 2002, 23, 736-748.	0.7	91
2	MicroRNAâ€10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Science, 2010, 101, 1997-2004.	1.7	88
3	The Molecular Biology of Vestibular Schwannomas: Dissecting the Pathogenic Process at the Molecular Level. Otology and Neurotology, 2006, 27, 197-208.	0.7	61
4	AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology, 2011, 13, 983-999.	0.6	60
5	The Human POLD1 Gene. Journal of Biological Chemistry, 1997, 272, 4869-4882.	1.6	59
6	Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European Journal of Cancer, 2009, 45, 1709-1720.	1.3	55
7	Phosphatidylinositol 3-Kinase/AKT Pathway Activation in Human Vestibular Schwannoma. Otology and Neurotology, 2008, 29, 58-68.	0.7	49
8	The role of Drosophila Merlin in spermatogenesis. BMC Cell Biology, 2008, 9, 1.	3.0	47
9	Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth. Cancer Research, 2013, 73, 792-803.	0.4	44
10	Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget, 2015, 6, 1981-1994.	0.8	38
11	Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope, 2012, 122, 174-189.	1.1	37
12	LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2. Oncogene, 2014, 33, 3571-3582.	2.6	37
13	Multiple Transcription Initiation Sites, Alternative Splicing, and Differential Polyadenylation Contribute to the Complexity of Human Neurofibromatosis 2 Transcripts. Genomics, 2002, 79, 63-76.	1.3	36
14	Evolution and origin of merlin, the product of the Neurofibromatosis type 2 (NF2) tumor-suppressor gene. BMC Evolutionary Biology, 2005, 5, 69.	3.2	36
15	Retinoblastoma???Cyclin-Dependent Kinase Pathway Deregulation in Vestibular Schwannomas. Laryngoscope, 2002, 112, 1555-1561.	1.1	34
16	Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Experimental Neurology, 2018, 299, 299-307.	2.0	31
17	Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Molecular Cancer Therapeutics, 2017, 16, 2387-2398.	1.9	30
18	Molecular studies of vestibular schwannomas: a review. Current Opinion in Otolaryngology and Head and Neck Surgery, 2007, 15, 341-346.	0.8	29

#	Article	IF	Citations
19	Regulation of the Neurofibromatosis 2 gene promoter expression during embryonic development. Developmental Dynamics, 2006, 235, 2771-2785.	0.8	27
20	Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget, 2017, 8, 31666-31681.	0.8	27
21	Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2â€“associated schwannomas reveals differences in efficacy and drug resistance development. Neuro-Oncology, 2019, 21, 486-497.	0.6	27
22	Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncology, 2016, 18, 1265-1277.	0.6	24
23	Natural Compounds as Potential Treatments of NF2-Deficient Schwannoma and Meningioma. Otology and Neurotology, 2013, 34, 1519-1527.	0.7	23
24	EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro-Oncology, 2018, 20, 1185-1196.	0.6	22
25	Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS ONE, 2021, 16, e0252048.	1.1	19
26	Growth of Benign and Malignant Schwannoma Xenografts in Severe Combined Immunodeficiency Mice. Laryngoscope, 2006, 116, 2018-2026.	1.1	17
27	Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS ONE, 2018, 13, e0197350.	1.1	17
28	Treatment of Vestibular Schwannoma Cells With ErbB Inhibitors. Otology and Neurotology, 2012, 33, 244-257.	0.7	15
29	Cyclin D1 and D3 Expression in Vestibular Schwannomas. Laryngoscope, 2006, 116, 423-426.	1.1	14
30	Early phase clinical studies of <scp>AR</scp>â€42, a histone deacetylase inhibitor, for neurofibromatosis type 2â€associated vestibular schwannomas and meningiomas. Laryngoscope Investigative Otolaryngology, 2021, 6, 1008-1019.	0.6	14
31	Analysis of the Human Neurofibromatosis Type 2 Gene Promoter and its Expression. Otolaryngology - Head and Neck Surgery, 2000, 123, 413-418.	1.1	11
32	Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Molecular Cancer Therapeutics, 2020, 19, 731-741.	1.9	10
33	Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma. Methods in Molecular Biology, 2016, 1427, 59-72.	0.4	9
34	Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Frontiers in Oncology, 2021, 11, 698192.	1.3	8
35	Molecular Biology of Vestibular Schwannomas. Methods in Molecular Biology, 2009, 493, 163-177.	0.4	7
36	Over-expression of p73Î² results in apoptotic death of post-mitotic hNT neurons. Journal of the Neurological Sciences, 2006, 240, 1-6.	0.3	5

#	Article	IF	Citations
37	Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. Planta Medica, 2021, 87, 937-948.	0.7	4
38	Evolution and Origin of HRS, a Protein Interacting with Merlin, the Neurofibromatosis 2 Gene Product. Gene Regulation and Systems Biology, 2009, 3, GRSB.S3106.	2.3	3
39	HDAC-42 as a potential radiosensitizer for human schwannomas. Otolaryngology - Head and Neck Surgery, 2009, 141, P81-P81.	1.1	0
40	Novel inhibitors of vestibular schwannomas and meningiomas. Otolaryngology - Head and Neck Surgery, 2009, 141, P87-P88.	1.1	0
41	CSIG-42. HIGH THROUGHPUT KINOME AND TRANSCRIPTOME ANALYSES REVEAL NOVEL THERAPEUTIC TARGETS IN NF2-DEFICIENT MENINGIOMA. Neuro-Oncology, 2018, 20, vi52-vi52.	0.6	0